JP2016539138A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539138A5
JP2016539138A5 JP2016536145A JP2016536145A JP2016539138A5 JP 2016539138 A5 JP2016539138 A5 JP 2016539138A5 JP 2016536145 A JP2016536145 A JP 2016536145A JP 2016536145 A JP2016536145 A JP 2016536145A JP 2016539138 A5 JP2016539138 A5 JP 2016539138A5
Authority
JP
Japan
Prior art keywords
optionally substituted
benzo
cyclohepta
pyridazin
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016536145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539138A (ja
JP6992960B2 (ja
Filing date
Publication date
Priority claimed from GB201321227A external-priority patent/GB201321227D0/en
Priority claimed from GB201323021A external-priority patent/GB201323021D0/en
Application filed filed Critical
Priority claimed from PCT/GB2014/053548 external-priority patent/WO2015082887A2/en
Publication of JP2016539138A publication Critical patent/JP2016539138A/ja
Publication of JP2016539138A5 publication Critical patent/JP2016539138A5/ja
Application granted granted Critical
Publication of JP6992960B2 publication Critical patent/JP6992960B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016536145A 2013-12-02 2014-11-28 キナーゼ阻害剤の用途 Expired - Fee Related JP6992960B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1321227.9 2013-12-02
GB201321227A GB201321227D0 (en) 2013-12-02 2013-12-02 Use of kinase inhibitors
GB201323021A GB201323021D0 (en) 2013-12-24 2013-12-24 Use of kinase inhibitors
GB1323021.4 2013-12-24
PCT/GB2014/053548 WO2015082887A2 (en) 2013-12-02 2014-11-28 Use of kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080908A Division JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Publications (3)

Publication Number Publication Date
JP2016539138A JP2016539138A (ja) 2016-12-15
JP2016539138A5 true JP2016539138A5 (enExample) 2017-12-28
JP6992960B2 JP6992960B2 (ja) 2022-02-03

Family

ID=52016110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016536145A Expired - Fee Related JP6992960B2 (ja) 2013-12-02 2014-11-28 キナーゼ阻害剤の用途
JP2020080908A Pending JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020080908A Pending JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Country Status (4)

Country Link
US (1) US9801880B2 (enExample)
EP (1) EP3076966A2 (enExample)
JP (2) JP6992960B2 (enExample)
WO (1) WO2015082887A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3205654T3 (pl) 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
LT3873903T (lt) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CN115504967A (zh) * 2021-06-23 2022-12-23 南京正大天晴制药有限公司 作为axl抑制剂的1,2,4-三唑化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163547A0 (en) * 2002-02-12 2005-12-18 Quark Biotech Inc Use of the axl receptor for diagnosis and treatment of renal disease
AU2004267420A1 (en) * 2003-08-11 2005-03-03 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
EP1917965A1 (en) * 2003-11-18 2008-05-07 Novartis AG Inhibitors of the mutant form of KIT
PL2078010T3 (pl) * 2006-12-29 2014-07-31 Rigel Pharmaceuticals Inc Triazole podstawione policyklicznym heteroarylem użyteczne jako inhibitory Axl
KR100900289B1 (ko) 2007-06-21 2009-05-29 엘지전자 주식회사 직교 주파수 분할 다중화 시스템에서 제어 채널을 송수신하는 방법
JP2011522212A (ja) 2007-10-19 2011-07-28 セル・シグナリング・テクノロジー・インコーポレイテツド 癌の分類および使用法
US9266890B2 (en) * 2009-01-06 2016-02-23 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2387395B1 (en) 2009-01-16 2014-10-15 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US8603740B2 (en) 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
BR112013026744B1 (pt) * 2011-04-21 2022-05-17 Origenis Gmbh Compostos heterocíclicos, seus usos e seus intermediários, e composição farmacêutica

Similar Documents

Publication Publication Date Title
JP2016539138A5 (enExample)
JP2020105211A5 (enExample)
JP5529004B2 (ja) Hsp90阻害剤として有用なトリアジノンおよびジアジノン誘導体
JP5441691B2 (ja) Hsp90活性を調節するトリアゾール化合物
JP7014731B2 (ja) 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
TWI641371B (zh) 免疫相關及發炎疾病之治療
CN105492439B (zh) 作为溴结构域抑制剂的取代的双环化合物
AU2014272776C1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2016517857A5 (enExample)
JP2009542716A5 (enExample)
WO2013171639A1 (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
JP2017511360A5 (enExample)
AU2018335617B2 (en) Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
WO2015082887A2 (en) Use of kinase inhibitors
JP2016525104A5 (enExample)
Mounika et al. An overview of CDK enzyme inhibitors in cancer therapy
US20220347176A1 (en) Phenyl-sulfamoyl.benzoyc acids as erap1 modulators
JP2015515477A (ja) Hsp90活性を調節する新規トリアゾール化合物
JP2011518168A5 (enExample)
AR044648A1 (es) Combinaciones terapeuticas
TW202131917A (zh) 併用醫藥
EP3624805A1 (en) Pyrazoloquinazolinone antitumor agents
TW202116301A (zh) 藥物組合及其用途
KR20250129099A (ko) 암 면역요법-관련 사이토카인 방출 증후군 완화를 위한 의약품 및 방법
JPWO2021126731A5 (enExample)